Karyopharm Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Karyopharm Therapeutics

29/07/2024 16:50

* Karyopharm Therapeutics Inc  KPTI.OQ   KPTI.O  is expected
to show a fall in quarterly revenue when it reports  results on
July 31 (estimated) for the period ending June 30 2024
    * The Newton Center Massachusetts-based  company is expected
to
report a 3.7% decrease in revenue to $36.179 million from $37.58
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Karyopharm Therapeutics
Inc is
for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karyopharm
Therapeutics Inc is $5.00​, above​ its last closing price
of $0.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.33       -0.33      -0.32     Beat    4.2
 Dec. 31 0001  -0.31       -0.31      -0.36     Missed  
 Sep. 30 2023  -0.28       -0.28      -0.30     Missed  -7.1​
 Jun. 30 2023  -0.35       -0.34      -0.29     Beat    15.3
 ​​Mar.        -0.36       -0.37      -0.30     Beat    18.5
 31 2023                                                
 Jan. 1 0001   -0.35       -0.35      -0.43     Missed  ​
 Jan. 1 0001   -0.58       -0.57      -0.45     Beat    20.4
 Jun. 30 2022  -0.63       -0.63      -0.62     Beat    2.1
 This summary was machine generated July 29 at 15:49 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)